Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks - Candesartan Antihypertensive Survival Evaluation in Japan Trial

被引:184
作者
Ogihara, Toshio [3 ]
Nakao, Kazuwa [1 ,2 ]
Fukui, Tsuguya [4 ]
Fukiyama, Kohshiro [5 ]
Ueshima, Kenji [2 ]
Oba, Koji [2 ]
Sato, Tosiya [6 ]
Saruta, Takao [7 ]
机构
[1] Kyoto Univ, Grad Sch Med, Dept Med & Clin Sci, Sakyo Ku, Kyoto 6068507, Japan
[2] Kyoto Univ, Grad Sch Med, EBM Res Ctr, Sakyo Ku, Kyoto 6068507, Japan
[3] Osaka Univ, Grad Sch Med, Osaka, Japan
[4] St Lukes Int Hosp, Tokyo, Japan
[5] Japan Seamans Relief Associat Moji Hosp, Fukuoka, Japan
[6] Kyoto Univ, Sch Publ Hlth, Grad Sch Med, Dept Biostat, Kyoto, Japan
[7] Keio Univ, Grad Sch Med, Tokyo, Japan
关键词
antihypertensive therapy; hypertension; cardiovascular diseases; angiotensin II; calcium channel blockers; clinical trials;
D O I
10.1161/HYPERTENSIONAHA.107.098475
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
The Candesartan Antihypertensive Survival Evaluation in Japan Trial was designed to compare the long-term effects of the angiotensin II receptor blocker candesartan and the calcium channel blocker amlodipine on the incidence of cardiovascular events, represented as a composite of sudden death and cerebrovascular, cardiac, renal, and vascular events in high-risk Japanese hypertensive patients. We conducted a prospective, randomized, open-label study with blinded assessment of the end point in 4728 Japanese hypertensive patients (mean age: 63.8 years; mean body mass index: 24.6 kg/m(2)). Patients were followed for an average of 3.2 years. Blood pressure was well controlled with both treatment-based regimens (systolic blood pressure/diastolic blood pressure: 136.1/77.3 mm Hg for candesartan-based regimens and 134.4/76.7 mm Hg for amlodipine-based regimens after 3 years). Primary cardiovascular events occurred in 134 patients with both the candesartan-and amlodipine-based regimens. The 2 treatment-based regimens produced no significant differences in cardiovascular morbidity or mortality in the high-risk Japanese hypertensive patients (hazard ratio: 1.01; 95% CI: 0.79 to 1.28; P=0.969). In each primary end point category, there was no significant difference between the 2 treatment-based regimens. New-onset diabetes occurred in fewer patients taking candesartan (8.7/1000 person-years) than in those taking amlodipine (13.6/1000 person-years), which resulted in a 36% relative risk reduction (hazard ratio: 0.64; 95% CI: 0.43 to 0.97; P=0.033). We disclosed that candesartan-based and amlodipine-based regimens produced no statistical differences in terms of the primary cardiovascular end point, whereas candesartan prevented new-onset diabetes more effectively than amlodipine.
引用
收藏
页码:393 / 398
页数:6
相关论文
共 20 条
[1]  
*ALLHAT COLL RES G, 2002, JAMA-J AM MED ASSOC, V283, P1967
[2]   Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) [J].
Brown, MJ ;
Palmer, CR ;
Castaigne, A ;
de Leeuw, PW ;
Mancia, G ;
Rosenthal, T ;
Ruilope, LM .
LANCET, 2000, 356 (9227) :366-372
[3]   Body-mass index and mortality in a prospective cohort of US adults [J].
Calle, EE ;
Thun, MJ ;
Petrelli, JM ;
Rodriguez, C ;
Heath, CW .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (15) :1097-1105
[4]   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].
Dahlöf, B ;
Devereux, RB ;
Kjeldsen, SE ;
Julius, S ;
Beevers, G ;
de Faire, U ;
Fyhrquist, F ;
Ibsen, H ;
Kristiansson, K ;
Lederballe-Pedersen, O ;
Lindholm, LH ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wedel, H .
LANCET, 2002, 359 (9311) :995-1003
[5]   INTERIM ANALYSIS - THE ALPHA-SPENDING FUNCTION-APPROACH [J].
DEMETS, DL ;
LAN, KKG .
STATISTICS IN MEDICINE, 1994, 13 (13-14) :1341-1352
[6]  
Fujishima M, 2001, HYPERTENS RES, V24, P613
[7]   Candesartan antihypertensive survival evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: Rationale, design, and methods [J].
Fukui, T ;
Rahman, M ;
Hayashi, K ;
Takeda, K ;
Higaki, J ;
Sato, T ;
Fukushima, M ;
Sakamoto, J ;
Morita, S ;
Ogihara, T ;
Fukiyama, K .
HYPERTENSION RESEARCH, 2003, 26 (12) :979-990
[8]  
*GLANT STUD GROUP, 1995, HYPERTENS RES, V18, P235
[9]   Drug therapy - Angiotensin receptors and their antagonists [J].
Goodfriend, TL ;
Elliott, ME ;
Catt, KJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (25) :1649-1654
[10]   Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:: principal results of the hypertension optimal treatment (HOT) randomised trial [J].
Hansson, L ;
Zanchetti, A ;
Carruthers, SG ;
Dahlöf, B ;
Elmfeldt, D ;
Julius, S ;
Ménard, J ;
Rahn, KH ;
Wedel, H ;
Westerling, S .
LANCET, 1998, 351 (9118) :1755-1762